PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
NYSE:MD • US58502B1061
21.52 USD
+0.45 (+2.14%)
At close: Feb 13, 2026
21.52 USD
0 (0%)
After Hours: 2/13/2026, 8:23:28 PM
We assign a fundamental rating of 5 out of 10 to MD. MD was compared to 102 industry peers in the Health Care Providers & Services industry. MD has an average financial health and profitability rating. MD is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make MD suitable for value investing!
1. Profitability
1.1 Basic Checks
- In the past year MD was profitable.
- MD had a positive operating cash flow in the past year.
- In multiple years MD reported negative net income over the last 5 years.
- MD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- MD has a better Return On Assets (7.37%) than 89.22% of its industry peers.
- MD has a Return On Equity of 18.21%. This is amongst the best in the industry. MD outperforms 86.27% of its industry peers.
- MD has a better Return On Invested Capital (10.25%) than 80.39% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for MD is in line with the industry average of 8.97%.
- The 3 year average ROIC (7.83%) for MD is below the current ROIC(10.25%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.37% | ||
| ROE | 18.21% | ||
| ROIC | 10.25% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
- With an excellent Profit Margin value of 8.44%, MD belongs to the best of the industry, outperforming 89.22% of the companies in the same industry.
- MD has a Operating Margin of 12.20%. This is amongst the best in the industry. MD outperforms 83.33% of its industry peers.
- In the last couple of years the Operating Margin of MD has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.2% | ||
| PM (TTM) | 8.44% | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- MD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for MD has been increased compared to 1 year ago.
- The number of shares outstanding for MD has been increased compared to 5 years ago.
- Compared to 1 year ago, MD has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 2.18 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
- MD has a Altman-Z score of 2.18. This is comparable to the rest of the industry: MD outperforms 52.94% of its industry peers.
- The Debt to FCF ratio of MD is 2.20, which is a good value as it means it would take MD, 2.20 years of fcf income to pay off all of its debts.
- MD has a better Debt to FCF ratio (2.20) than 77.45% of its industry peers.
- MD has a Debt/Equity ratio of 0.65. This is a neutral value indicating MD is somewhat dependend on debt financing.
- MD has a Debt to Equity ratio of 0.65. This is comparable to the rest of the industry: MD outperforms 55.88% of its industry peers.
- Although MD does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.65 | ||
| Debt/FCF | 2.2 | ||
| Altman-Z | 2.18 |
ROIC/WACC1.21
WACC8.44%
2.3 Liquidity
- MD has a Current Ratio of 1.83. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
- MD's Current ratio of 1.83 is fine compared to the rest of the industry. MD outperforms 71.57% of its industry peers.
- MD has a Quick Ratio of 1.83. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
- MD has a Quick ratio of 1.83. This is in the better half of the industry: MD outperforms 74.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
- MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.92%, which is quite impressive.
- MD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -15.01% yearly.
- Looking at the last year, MD shows a decrease in Revenue. The Revenue has decreased by -4.21% in the last year.
- The Revenue has been growing slightly by 2.49% on average over the past years.
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
3.2 Future
- MD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.64% yearly.
- MD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.71% yearly.
EPS Next Y44.07%
EPS Next 2Y22.97%
EPS Next 3Y16.76%
EPS Next 5Y7.64%
Revenue Next Year-4.52%
Revenue Next 2Y-0.98%
Revenue Next 3Y0.1%
Revenue Next 5Y2.71%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 10.55, which indicates a very decent valuation of MD.
- Compared to the rest of the industry, the Price/Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 91.18% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 26.68, MD is valued rather cheaply.
- Based on the Price/Forward Earnings ratio of 9.55, the valuation of MD can be described as reasonable.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 92.16% of the companies listed in the same industry.
- MD is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.55 | ||
| Fwd PE | 9.55 |
4.2 Price Multiples
- 82.35% of the companies in the same industry are more expensive than MD, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, MD is valued cheaper than 91.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.76 | ||
| EV/EBITDA | 7.24 |
4.3 Compensation for Growth
- MD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of MD may justify a higher PE ratio.
- A more expensive valuation may be justified as MD's earnings are expected to grow with 16.76% in the coming years.
PEG (NY)0.24
PEG (5Y)N/A
EPS Next 2Y22.97%
EPS Next 3Y16.76%
5. Dividend
5.1 Amount
- No dividends for MD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
21.52
+0.45 (+2.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-03 2025-11-03/bmo
Earnings (Next)02-19 2026-02-19/bmo
Inst Owners98.9%
Inst Owner Change-0.24%
Ins Owners1.87%
Ins Owner Change-2.29%
Market Cap1.85B
Revenue(TTM)1.92B
Net Income(TTM)162.19M
Analysts78.67
Price Target23.12 (7.43%)
Short Float %3.62%
Short Ratio3.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.41%
Min EPS beat(2)21.14%
Max EPS beat(2)39.68%
EPS beat(4)4
Avg EPS beat(4)32.13%
Min EPS beat(4)21.14%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)18.68%
EPS beat(12)7
Avg EPS beat(12)8.95%
EPS beat(16)9
Avg EPS beat(16)6.72%
Revenue beat(2)1
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)0.42%
Revenue beat(4)2
Avg Revenue beat(4)-0.67%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-2.24%
Revenue beat(12)2
Avg Revenue beat(12)-2.22%
Revenue beat(16)3
Avg Revenue beat(16)-2.43%
PT rev (1m)0%
PT rev (3m)35.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3%
EPS NY rev (1m)0%
EPS NY rev (3m)16.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.55 | ||
| Fwd PE | 9.55 | ||
| P/S | 0.96 | ||
| P/FCF | 6.76 | ||
| P/OCF | 6.37 | ||
| P/B | 2.08 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.24 |
EPS(TTM)2.04
EY9.48%
EPS(NY)2.25
Fwd EY10.47%
FCF(TTM)3.18
FCFY14.79%
OCF(TTM)3.38
OCFY15.69%
SpS22.39
BVpS10.37
TBVpS-4.42
PEG (NY)0.24
PEG (5Y)N/A
Graham Number21.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.37% | ||
| ROE | 18.21% | ||
| ROCE | 12.98% | ||
| ROIC | 10.25% | ||
| ROICexc | 13.79% | ||
| ROICexgc | 251.95% | ||
| OM | 12.2% | ||
| PM (TTM) | 8.44% | ||
| GM | N/A | ||
| FCFM | 14.22% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexgc growth 3Y26.95%
ROICexgc growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.65 | ||
| Debt/FCF | 2.2 | ||
| Debt/EBITDA | 2.24 | ||
| Cap/Depr | 72.01% | ||
| Cap/Sales | 0.86% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 112.59% | ||
| Profit Quality | 168.57% | ||
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | 2.18 |
F-Score8
WACC8.44%
ROIC/WACC1.21
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
EPS Next Y44.07%
EPS Next 2Y22.97%
EPS Next 3Y16.76%
EPS Next 5Y7.64%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
Revenue Next Year-4.52%
Revenue Next 2Y-0.98%
Revenue Next 3Y0.1%
Revenue Next 5Y2.71%
EBIT growth 1Y42.45%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year70.96%
EBIT Next 3Y20.58%
EBIT Next 5YN/A
FCF growth 1Y104.91%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y73.9%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%
PEDIATRIX MEDICAL GROUP INC / MD FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 5 / 10 to MD.
What is the valuation status for MD stock?
ChartMill assigns a valuation rating of 9 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 6 / 10.
What are the PE and PB ratios of PEDIATRIX MEDICAL GROUP INC (MD) stock?
The Price/Earnings (PE) ratio for PEDIATRIX MEDICAL GROUP INC (MD) is 10.55 and the Price/Book (PB) ratio is 2.08.